HugelArticles & NewsCompaniesFormer Allergan Exec Carrie Strom Named CEO of Hugel Following U.S. Launch of LetyboA seasoned aesthetics industry executive is taking the helm of a fast-expanding global brand—just as it makes a major move into the U.S. market.TreatmentsWith FDA Approval, K-Beauty Letybo Brings High-Purity Botulinum Toxin A to U.S. Injectable MarketLetybo, a common injectable for glabellar lines in South Korea, was approved by the FDA in 2024 and is now finding its way in U.S. practices as a leading neurotoxin next to alternatives like Botox, Dysport and Xeomin.
